By dissociating CD4-driven side effects from CD8-mediated antitumor responses, we think combination therapy could transform immunotherapy for cancer by bringing these treatments to cancer patients much earlier in their diagnosis, and even as upfront treatment rather than for late-stage metastatic disease. This evidence concerns the gene CD4 and metastatic neoplasm.